[Diagnosis and treatment in systemic amyloidosis].
Systemic amyloidosis is characterized by the involvement of multiple organs and the presence of an amyloid precursor protein in serum. This disorder is classified into four major forms: immunoglobulin light chain-derived (AL), reactive AA, dialysis-related (beta2M) and hereditary transthyretin (ATTR) type. Heart, kidney, gastrointestinal tract and peripheral nerves are commonly affected by amyloid deposition in systemic amyloidosis and histopathological demonstration of amyloid deposits on any of affected organs is the first step leading to the diagnosis of this disease. Immunohistochemical analysis of amyloid protein on tissue amyloid deposits is necessary to make classification of the disease and DNA testing is also useful in a hereditary form. Amyloidosis had been considered to be an incurable disease but during the past one decade several therapeutic approaches have been employed for the amyloidosis patients with diverse pathogenetic backgrounds: intravenous large dose of melphalan accompanied by autologous peripheral blood stem cell transplantation for AL amyloidosis and liver transplantation for hereditary ATTR type amyloidosis. As a result some amyloidosis patients have been rescued and are now enjoying their own social lives. It is likely that recent advance on the research of amyloidosis has changed the concept of this disease.
Ikeda
Shu-ichi
S
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto.
D000682:Amyloid / Q000032:analysis; D000686:Amyloidosis / Q000145:classification / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D016031:Liver Transplantation; D008558:Melphalan / Q000008:administration & dosage; D009154:Mutation; D036102:Peripheral Blood Stem Cell Transplantation; D011228:Prealbumin / Q000235:genetics
D000682:Amyloid; D011228:Prealbumin; D008558:Melphalan